




















dAnalytica Chimica Acta 589 (2007) 159–165
Solubilisation and binding characteristics of a recombinant 2-adrenergic
receptor expressed in the membrane of Escherichia coli for the
multianalyte detection of -agonists and antagonists
residues in food-producing animals
Sophie Danyi a,∗, Guy Degand a, Colette Duez b, Benoıˆt Granier c,
Guy Maghuin-Rogister a, Marie-Louise Scippo a
a Department of Food Sciences, Laboratory of Analysis, Faculty of Veterinary Medicine, University of Lie`ge, B43b,
bld de Colonster 20, Sart-Tilman, B-4000 Lie`ge, Belgium
b Center for Protein Engineering, University of Lie`ge, B6, alle´e de la Chimie 3, B-4000 Lie`ge, Belgium
c Unisensor SA., zoning industriel du Dossay, rue du Dossay 3, B-4020 Lie`ge Wandre, Belgium
Received 9 November 2006; received in revised form 19 February 2007; accepted 22 February 2007
Available online 25 February 2007
bstract
The number of substances with -agonistic activity, illegally introduced in meat production or in sports doping as anabolic or -blocking agents
s increasing. Analytical methods suited for their multianalyte detection are thus necessary. In this perspective, receptor assays were developed.
he research activities undertaken in this study describe the solubilisation of a recombinant human 2-adrenergic receptor produced in the inner
embrane of genetically modified Escherichia coli, using the detergent n-dodecyl--d-maltoside. Its potential to detect the presence of -agonists
r -blockers in biological samples was evaluated. The solubilised 2-adrenergic receptor retained its binding affinity in a radio-receptor assay
ased on the competition for the binding to receptors between a ligand (-agonist or antagonist) and the radioligand [125I]iodocyanopindolol.
he IC50 values ranged from 5 ± 1 × 10−8 M (clenbuterol) to 8 ± 2 × 10−6 M (isoxsuprine) for the -agonists tested and from 1.5 ± 0.2 × 10−10 Mcarazolol) to 1.2 ± 0.2 × 10−5 M (metoprolol) for the -blockers tested. It was shown to have a lower limit of detection than a radio-receptor assay
sing the solubilised 2-adrenoceptor expressed in a mammalian cell line. The solubilised recombinant human 2-adrenoreceptor expressed in E.
oli would be a useful tool to develop non radioactive multianalyte screening methods.
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. Introduction
The use of-agonists as growth promoters in meat production
s banned within the EU (directive 96/22/EC). The consumption
f these compounds under the form of residues, especially in
iver where the drugs concentrate, but even from meat when large
ver dosage occurs, can lead to severe intoxication in humans
1–3]. Analytical methods are thus required to monitor the illegal
resence of these residues to provide assurance to the consumer
n the quality and safety of food and to ensure enforcement
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f government tolerances and compliance with export/import
equirements. Several analytical methods have been described
or the detection of -agonists residues in urine and animal
issue samples. Confirmatory analysis of -agonists is based
n gas chromatography–mass spectrometry (GC–MS) [4] or
iquid chromatography–mass spectrometry LC–MS(-MS) [5],
hese methods are time-consuming, expensive and unsuited to
he screening of large series of samples. The screening methods
sed are often immunoassays, such as enzyme immunoassay
EIA). Several methods for urine [6–8] and hair [9,10] have
een described and various EIA-kits are commercially available.
adio-immunoassays (RIA) have also been developed [11]. A
ore recent detection technique is immunobiosensor analysis
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its using the surface plasmon resonance (SPR) technology are
vailable. All these screening methods have the advantage of
ffering low limits of detection but they are too selective.
Even using antibodies with broad cross-reactivity, only a
imited number of -agonist residues are detected. With the
resence on the black market of new compounds, their detection
ecomes increasingly problematical as existing analytical meth-
ds are not adapted for the detection of new molecules [13]. The
dvantage of receptor-based assays in residue detection is their
apability of detecting a broader spectrum of similar compounds
generic assay), including new structurally related molecules for
hich no detailed information is known.
The 2-adrenergic receptor is a transmembrane protein of G
rotein-coupled receptors family (GPCRs). Upon receptor acti-
ation by an agonistic ligand binding, the receptor induces a
onformational change in the associated heterotrimeric G pro-
ein. The activation of G protein leads to a signal transduction
ascade which mediates cellular responses by modulating spe-
ific effector enzymes, such as adenylyl cyclase resulting in
n increase of 3′-5′-cyclic adenosine monophosphate (cAMP)
14]. Some authors have reported the effects of agonists and
ntagonists of -adrenoceptors in eukaryotic cells quantifying
ellular cAMP levels by the use of a luciferase reporter gene
ssay [15,16]. The goal of these studies was essentially to iden-
ify the presence or activity of -adrenoceptors in particular cell
ines or the effect of specific ligands on the receptors instead of
eveloping new -agonists detection methods.
The 2-adrenergic receptor has already been function-
lly expressed in a variety of different organisms including
nsect and mammalian cells [17] or Escherichia coli [18,19].
adio-receptor assays (RRA) have already been described for
ultianalyte detection of -agonist residues using natural mem-
rane bound 2-adrenergic receptors prepared from bovine teat
uscles [20], or recombinant 2-adrenoreceptors expressed in
embranes of a transfected Chinese hamster ovary (CHO) cell
ine [21] or expressed in human embryonic kidney cells [22].
n the past, we developed a multi-residue screening method for
he detection of 2-adrenergic residues in urine samples using
radioactive tracer and a genetically modified E. coli express-
ng the human 2-adrenergic receptor in their inner membrane
23]. The ultimate objective is to develop a multianalyte detec-
ion of -agonists and -blockers in biological samples without
he use of radioactive ligands, such as dipstick assays. This
aper describes the solubilisation of the recombinant human
2-adrenergic receptor produced in the inner membrane of
enetically modified E. coli. The solubilised protein keeps its
apacity to bind agonists and antagonists and shows its potential
o be used in the development of non radioactive multi-residue
creening methods.
. Experimental
.1. Chemicals and reagentsEscherichia coli KS303 transformed by pMES plasmid [24]
as a gift of A.D. Strosberg (Institut Cochin, Paris, France).
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used to the promoter of the maltose-binding protein of E. coli
MalE) followed by a part of the MalE gene coding for the first
6 amino acids of the MalE protein. The 2-adrenergic receptor
as produced as a fusion protein with a part of MalE protein
o increase the hydrophilicity of the receptor. This hydrophilic
artner, as periplasmic protein secreted through the bacterial
nner membrane, allows the correct insertion and folding of the
eceptor in the bacterial membrane.
Luria broth (LB) medium and Luria agar for the maintenance
nd propagation of E. coli were purchased by Gibco-
RL Life Technologies (Gaithersburg, Maryland), as well as
mpicillin sodium. Sterilized d-(+)-glucose solution (45%), d-
+)-maltose monohydrate, deoxyribonuclease I, ribonuclease
, phenylmethylsulfonyl fluoride (PMSF), leupeptine, pepsta-
ine A, the detergent n-dodecyl--d-maltoside, trizma base,
otassium phosphate, ethylenediaminetetraacetic acid (EDTA),
hloramine T, sodium metabisulfite were supplied by Sigma (St.
ouis, Missouri). Lysozyme was purchased from Belovo (Bas-
ogne, Belgium). Iodine resublimed was from UCB (Brussels,
elgium) and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
cid (Hepes) was purchased by Boehringer (Ingelheim, Ger-
any). Cyanopindolol (CYP) was a gift from Novartis Pharma
Basel, Switzerland). Iodine-125 (1 mCi Na125I, 37.0 MBq) was
upplied by Amersham Biosciences (Buckinghamshire, UK).
he bicinchoninic acid (BCA) protein assay, used for the deter-
ination of protein concentration in bacterial preparations, was
urchased from Pierce (Rockford, Illinois). All chemicals were
f analytical grade.
The 2-agonists clenbuterol·HCl, fenoterol·HBr, salbuta-
ol, terbutaline·1/2 H2SO4, ritodrine·HCl and -blockers
-propranolol·HCl, alprenolol·HCl and nadolol were
btained from Sigma (St. Louis, Missouri). The 2-agonists
arbuterol·HCl, ractopamine·HCl and isoxsuprine·HCl were
rom BGA (Berlin, Germany), cimaterol was from Boehringer
ngelheim (Mannheim, Germany). The -blocker carazolol and
2-agonist mabuterol were gifts from C.E.R., Laboratory of
ormonology (Marloie, Belgium). The -blocker metoprolol
artrate was supplied by ICN Biomedicals (Solon, Ohio).
.2. Equipment
Standard laboratory apparatus was used throughout for the
reparation of media and chemical solutions.
A Heraeus minifuge T Centrifuge (Hanau, RFA) was used to
ecover the bacteria during the 2-adrenergic receptor produc-
ion.
A Centrikon T-2070 ultracentrifuge from Kontron Instru-
ents (Milan, Italy) with Sorvall rotor T-55.38 (Newtown,
onnecticut) was used to isolate the bacterial membranes and
uring the solubilisation steps of the2-adrenergic receptor from
he isolated membranes. A MSE Analis sonicator (Suarle´e, Bel-
ium) was used for E. coli cells disruption. Amicon Centriplus
M-30 from Millipore (Bedford, Massachusetts) was used tooncentrate the preparation of solubilised 2-adrenergic recep-
ors. A Beckman J2-21 centrifuge with a rotor JA-20 (Palo
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A solvent delivery system Waters 600 (Milford, Mas-
achusetts) and a LC column Symmetry C18 (4.5 × 150 mm,
m) from Waters were used to purify the radioligand [125I]-
odocyanopindolol. A 3025 vacuum filtration manifold from
illipore (Bedford, Massachusetts) and glass microfibre fil-
ers GF/B from Whatman (Maidstone, UK) were used to filter
amples prior analysis by radio-receptor assay. The filters were
re-soaked in 0.5% polyethylenimine (Sigma, St. Louis) to
etain, by ionic interactions, the isolated membranes or solu-
ilised proteins on the filters. Radioactivity was measured using
Cobra II Auto-Gamma counter from Packard Instrument Com-
any (Meriden, Connecticut).
.3. Production of β2-adrenergic receptors
Recombinant E. coli KS303, stored at −70 ◦C, were grown
t 37 ◦C in LB medium containing 100g mL−1 ampicillin
nd 1% d-(+)-glucose (repressing the 2-adrenergic receptor
xpression) till an A600 value of 1. The bacterial suspension
as centrifuged at 3700 × g for 10 min at 4 ◦C; the bacterial
ellet was washed in LB medium free of glucose and cen-
rifuged as described. Expression of the recombinant human
2-adrenergic receptor was induced in LB medium contain-
ng 100g mL−1 ampicillin and 1% d-(+)-maltose for 5–6 h
t 30 ◦C. The bacterial suspension was centrifuged as described
nd the bacterial pellet was resuspended in 10 mM Hepes, pH
.5 and homogenised using a Dounce homogeniser. The final
uspension was frozen in liquid nitrogen and stored at −70 ◦C
r used immediately in isolation of cell membranes procedures.
.3.1. Preparation and fractionation of E. coli membranes
E. coli cells were harvested by centrifugation (15 min at
700 × g and 4 ◦C) and membrane fractionation was performed
y sucrose-density centrifugation using a modification of the
ethod described by Chapot et al. [19]. Bacteria were resus-
ended in 10 mM Hepes, pH 7.5 containing 20% (m/m) sucrose,
0g mL−1 deoxyribonuclease I, 30g mL−1 ribonuclease A,
mg mL−1 lysozyme, 1 mM PMSF, 5g mL−1 leupeptine,
g mL−1 pepstatine A and sonicated at high power for 2 min,
eeping on ice for 30 s between each sonication of 20 s. Unbro-
en cells were removed by centrifugation at 3700 × g for 15 min
t 4 ◦C. The supernatant was layered on a sucrose gradient con-
isting of 3 mL 60% (m/v) sucrose, 6 mL 42.5% (m/v) sucrose
nd 15 mL 25% (m/v) sucrose (in 10 mM Hepes, pH 7.5 con-
aining 5 mM EDTA) and centrifuged at 100,000 × g for 16 h at
◦C. Two fractions corresponding to the inner and outer mem-
ranes of E. coli were collected from the gradient, homogenised
sing a Dounce homogeniser. The final suspension was frozen in
iquid nitrogen and stored at −70 ◦C or assayed for protein con-
entration by the bicinchoninic acid (BCA) method, similar to
he Lowry procedure [25], or used immediately in solubilisation
rocedures..3.2. Solubilisation of β2-adrenergic receptors
The membrane suspension was mixed with a 0.5% (m/v)
-dodecyl--d-maltoside solution containing 1 mM PMSF,
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bilisation of the suspension was performed by four vortexing
ycles for 10 s keeping the preparation on ice for 15 min before
ach agitation. Non solubilised protein was removed by cen-
rifugation at 150,000 × g for 30 min at 4 ◦C. The resulting
upernatant was concentrated by ultrafiltration using an Amicon
entriplus centrifuge filter device. The final solubilised receptor
reparation was frozen in liquid nitrogen and stored at −70 ◦C
r assayed for protein concentration by the bicinchoninic acid
BCA) method.
.4. [125I]iodocyanopindolol synthesis
125I-CYP was synthesized in our laboratory by a modifi-
ation of the methods of Engels [26] and Moretti-Rojas [27].
0L of CYP solution (20g mL−1 in 13 mM HCl) was added
o 40L of 0.3 M potassium phosphate buffer, pH 7.6 and
0L of the mixture were incubated with 1 mCi Na125I (10L)
nd 5 mg mL−1 chloramine T (10L) for 1 min with shaking.
eaction was terminated by adding 10L 30 mg mL−1 sodium
etabisulfite and 0.3 M potassium phosphate buffer, pH 7.6 was
dded to obtain a total volume of 170L. Purification of the radi-
ligand was performed by HPLC. The mobile phase was 10 mM
otassium phosphate buffer, pH 7.5 containing 40% methanol
solvent A) or 80% methanol (solvent B). The flow rate was
mL min−1 and the injection volume was 170L. The gradient
lution conditions were: from 0 min to 10 min, 100% of solvent
; then from 10 min to 50 min, transition from 100% of sol-
ent A to 100% of solvent B in a linear way. Retention time of
odine-125 was 3 min, unlabelled CYP: 18 min and 125I-CYP:
5 min.
.5. Preparation of standard solutions
Stock solutions of 1 mg mL−1 2-agonists or-blockers were
repared by dissolving the compound in methanol and stored at
20 ◦C. Standard solutions were prepared by dilution of stock
olutions with 50 mM trizma base-HCl, pH 8.0. The concentra-
ions ranged from 10−4 M to 10−10 M for the 2-agonists and
rom 10−6 M to 10−11 M for the -blockers.
.6. Binding assays
All binding assays were performed in triplicate in T buffer:
0 mM trizma base-HCl, pH 8.0.
.6.1. Saturation experiments
150L of isolated E. coli membranes preparation or mem-
ranes solubilisate expressing the2-adrenergic receptor (20g
f total proteins) were incubated with 50L of increasing con-
entrations of tracer 125I-CYP and 50L of T buffer (total tracer
inding, Bo) or 50L of 10M l-propranolol (non-specific
inding). After incubation for 30 min at 37 ◦C, binding reactions
ere terminated by adding 4 mL of ice cold T buffer and rapid
ltration through GF/B glass microfibre filters (pre-soaked in
buffer containing 0.5% polyethylenimine) to separate bound
nd free fractions. The filters were washed four times with ice
















































Fig. 1. Specific binding of 125I-CYP to the 2-adrenergic receptor is a saturable
process. The Scatchard transformation of the saturation curve given in the inset
indicates the presence of a single class of binding sites with a KD value of
15 ± 4 pM and a Bmax value of 378 ± 29 fmol mg−1 of solubilised total pro-
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old T buffer and bound radioactivity was measured with a 
ounter.
.6.2. Inhibition experiments
150L of isolated E. coli membranes preparation or mem-
ranes solubilisate expressing the2-adrenergic receptor (20g
f total proteins) were incubated with 50L of 50 pM tracer
25I-CYP and 50L of T buffer (Bo) or 50L of 10M
-propranolol (non-specific binding) or 50L of solutions con-
aining increasing concentrations of -agonists or -blockers
tandards. Binding reactions were terminated as described in
ection 2.6.1.
.7. Calculation
Results were calculated by subtracting the non-specific bind-
ng counts from the total binding counts at each radioligand
oncentration (in Section 2.6.1) or at each-agonists,-blockers
tandards concentration (in Section 2.6.2). In receptor assay,
he non-specific binding is defined as being the fraction of the
otal tracer binding to receptors which is not displaced by a
igh concentration of non radioactive ligand. The -blocker l-
ropranolol was used in excess (10M) for the estimation of
he non-specific binding in all the experiments.
In Section 2.6.1, results were plotted graphically (specific
racer binding versus tracer concentration). The Bmax (concen-
ration of specific binding sites) and KD values (equilibrium
issociation constant of the tracer) were obtained after Scatchard
28] linear transformation of the data from the saturation curve
sing Microsoft Excel software.
In Section 2.6.2, the maximum tracer binding expressed in
ercent was plotted versus log of ligand concentration. The IC50
molar concentration of unlabeled ligand inhibiting binding of
adioactive tracer by 50%) was calculated from inhibition curves
tted by linearization using Microsoft Excel where the specific
racer binding expressed in logit function was plotted versus log
f ligand concentration. The binding dissociation constant Ki
alues (concentration of the inhibitor that bind to half of binding
ites at equilibrium) were calculated according to the following
quation: Ki = IC50/[2(L−Lo]/Lo) + 1 + (L/KD)] [29] where Lo
nd L are the molar concentrations of free 125I-CYP, respec-
ively, in absence of inhibitor and at the inhibition concentration
orresponding to IC50.
. Results and discussion
In this study, the solubilisation of the human 2-adrenergic
eceptor produced in the inner membrane of genetically modified
. coli was successfully performed using the non-ionic detergent
-dodecyl--d-maltoside. The solubilisation and purification
f 2-adrenergic receptors in eukaryotic cells were described
n many publications but the objective of the authors was
enerally to obtain large amounts of receptors to study their
tructural and biochemical properties instead their binding
haracteristics after the solubilisation procedure. The glyco-
ide digitonin was the non-ionic detergent commonly used




Eas incubated at 37 ◦C with increasing concentrations of tracer 125I-CYP for
0 min. Results are means of three experiments performed in triplicate.
embranes of eukaryotic cells [30,31]. The alkylglucoside n-
-d-dodecyl maltoside, which efficiently solubilise membrane
roteins, was used in some publications for the solubilisation
f human 2-adrenergic receptors from insect cells [32,33].
ne method was described for the solubilisation of the human
2-adrenergic receptor expressed in the inner membrane of
. coli using sucrose dodecanoyl instead n--d-dodecyl mal-
oside that, interacting with the MalE part of the fusion
rotein, prevented the receptor purification on a specific column
34].
The properties of solubilised 2-adrenergic receptors were
nvestigated by RRA using the radioactive tracer 125I-CYP.
he specific binding of 125I-CYP to solubilised receptors was
aturable as illustrated in Fig. 1. The Scatchard analysis of
he saturation curve given in the inset indicated the presence
f a single, homogeneous class of binding sites. The calcu-
ated concentration of binding sites Bmax (x-intercept) was
78 ± 29 fmol mg−1 of solubilised total proteins. The calcu-
ated receptor concentration was 14 ± 1 pmol L−1 of culture
edium and 217 ± 18 pmol L−1 of final concentrated prepa-
ation. The equilibrium dissociation constant value KD (the
egative reciprocal of the slope) was 15 ± 4 pM. From the results
eported in Table 1 was calculated the yield of binding pro-
eins obtained from the different preparations of 2-adrenergic
eceptors: the binding sites recovery from isolated membranes
reparation was about 90% in comparison with the Bmax
btained with whole bacteria; it was about 57% and 51%
rom the solubilised receptor preparation in comparison, respec-
ively, with the Bmax calculated from isolated membranes and
hole bacteria. The receptor concentration in the solubilised
reparation was about 2 and 25 times lower in comparison,
espectively, with isolated membranes and whole bacteria but
he receptor retained its binding affinity for the radioligand
fter the long steps of the preparation and fractionation of
. coli membranes and the solubilisation procedures. Bind-
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Table 1
Characteristics of the human 2-adrenergic receptor expressed in the inner membrane of E. coli
Whole bacteria Isolated membranes Solubilised proteins
Bmax values (fmol mg−1 total proteins)a 739 ± 54 664 ± 40 378 ± 29
Receptor concentration (pmol L−1 culture medium) 413 ± 16 30 ± 3 14 ± 1
Receptor concentration (pmol L−1 concentrated preparation 5240 ± 99 451 ± 38 217 ± 18






































Values are mean ± s of experiments performed in triplicate (n = 3)
a Number of binding sites.
b Dissociation constant.
ng characteristics of a solubilised 2-adrenoreceptor expressed
n membranes of a transfected CHO cell line were previ-
usly reported (Bmax value of 13 pmol mg−1 of membrane
roteins and 550 ± 100 fmol mg−1 of solubilised proteins; KD
alue of 390 pM) [21], as well as a membrane bound 2-
drenergic receptor expressed in human embryonic kidney cells
Bmax value of 17 pmol mg−1 of membrane proteins; KD value
f 281 pM) [22]. Although production level of 2-adrenergic
eceptors reported in E. coli was lower than in eukaryotic
ells, its affinity for the radioactive ligand (expressed by the
D value) was higher, indicating a better limit of detec-
ion.
The inhibition of 125I-CYP binding to the solubilised recep-
or was investigated for different 2-agonists and -blockers,
ith clenbuterol as reference, and the results plotted graphi-
ally, as shown respectively in Fig. 2A and B. The IC50 values
molar concentration of ligand inhibiting binding of 125I-CYP






nhibition of 125I-CYP binding to the solubilised 2-adrenergic receptor expressed
btained using a solubilised 2-adrenergic receptor expressed in mammalian cells (C
E. coli 2AR
Tracer: [125I]iodocyanopindolol
IC50 valuesb (M) Ki val
-Agonists
Clenbuterol (Reference) 5.0 ± 1.0 × 10−8 2.1 ±
Mabuterol 6.0 ± 1.0 × 10−8 2.7 ±
Cimaterol 1.7 ± 0.6 × 10−7 9.0 ±
Fenoterol 3.2 ± 0.2 × 10−7 1.5 ±
Ractopamine 8.0 ± 1.0 × 10−7 3.8 ±
Salbutamol 8.0 ± 2.0 × 10−7 4.1 ±
Carbuterol 1.4 ± 0.2 × 10−6 7.0 ±
Terbutaline 5.9 ± 0.3 × 10−6 2.9 ±
Ritodrine 7.0 ± 1.0 × 10−6 3.3 ±
Isoxsuprine 8.0 ± 2.0 × 10−6 3.7 ±
-Blockers
Carazolol 1.5 ± 0.2 × 10−10 3.3 ±
l-Propranolol 5.0 ± 1.3 × 10−10 1.1 ±
Alprenolol 1.8 ± 0.4 × 10−9 4.6 ±
Nadolol 3.7 ± 0.9 × 10−8 5.0 ±
Metoprolol 1.2 ± 0.2 × 10−5 8.6 ±
alues are mean ± s of experiments performed in triplicate (n = 3).
a Data from Meenagh et al. [21].
b Molar concentration of ligand inhibiting binding of radioligand by 50%.
c Equilibrium dissociation constant.
d Not available.nhibitor–receptor complex) for each ligand tested were calcu-
ated from sigmoidal inhibition curves linearized as described
n Section 2.7 and are listed in Table 2. The solubilised recep-
or was able to bind a broad spectrum of structurally diverse
igands both -agonists, as clenbuterol, and -blockers, as
arazolol. From all the molecules tested, the -blockers cara-
olol (IC50 value of 1.5 ± 0.2 × 10−10 M), l-propranolol (IC50
alue of 5.0 ± 1.3 × 10−10 M) and alprenolol (IC50 value of
.8 ± 0.4 × 10−9 M) showed the highest binding affinity for the
2-adrenergic receptor produced in E. coli. From the-agonists,
he aniline-type -agonists, such as clenbuterol (IC50 value
f 5 ± 1 × 10−8 M), mabuterol (IC50 value of 6 ± 1 × 10−8 M)
nd cimaterol (IC50 value of 1.7 ± 0.6 × 10−7 M) had the
ighest affinity. The phenolic-type -agonists, such as rac-
opamine, salbutamol and fenoterol were recognized by the
eceptor with a 10 times lower affinity than clenbuterol. The
-agonists terbutaline, ritodrine, isoxsuprine and the -blocker
etoprolol showed the lowest affinity. In comparison with




uesc (M) IC50 values (M) Ki values (M)
0.4 × 10−8 6.6 ± 0.7 × 10−7 4.0 ± 0.4 × 10−7
0.5 × 10−8 4.3 ± 1.5 × 10−7 2.7 ± 0.9 × 10−7
3.2 × 10−8 3.7 ± 1.5 × 10−6 2.3 ± 0.9 × 10−6
0.1 × 10−7 N.A.d N.A.
0.7 × 10−7 1.1 ± 0.6 × 10−5 6.9 ± 3.9 × 10−5
0.9 × 10−7 N.A. N.A.
1.0 × 10−7 N.A. N.A.
0.1 × 10−6 N.A. N.A.
0.4 × 10−6 N.A. N.A.
0.7 × 10−6 N.A. N.A.
0.7 × 10−10 N.A. N.A.
0.1 × 10−9 N.A. N.A.
1.3 × 10−9 N.A. N.A.
1.9 × 10−9 N.A. N.A.
1.7 × 10−6 N.A. N.A.
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Fig. 2. Inhibition of 125I-CYP binding to the 2-adrenergic receptor by -
agonists (A) or -blockers (B) in comparison with the reference -agonist














































[eins) was incubated at 37 ◦C with 50 pM tracer 125I-CYP and increasing
oncentrations of ligands for 30 min. Results are means of three experiments
erformed in triplicate.
radio-receptor assay using the solubilised 2-adrenoceptors
xpressed in membranes of a CHO cell line and the radi-
ligand [3H]dihydroalprenolol [21], the radio-receptor assay
sing the E. coli-receptor should allow a better limit of
etection for -agonist residues, with an affinity for clen-
uterol, mabuterol and cimaterol about 10 times and 100 times
igher for ractopamine than the CHO-receptor, as shown in
able 2.
. Conclusions
The results obtained in this study show the ability of the
eceptor to bind structurally different -agonists and -blockers
nd its potential to detect new compounds with agonistic or
ntagonistic activity. Furthermore, manipulations of recombi-
ant proteins produced in E. coli can be performed, under
eproducibility conditions, more quickly and at a lower cost
han in eukaryotic cells. In conclusion, the solubilised recombi-
ant  -adrenergic receptor would be a useful tool to develop2
on radioactive multianalyte screening methods in analysis of
esidues in foods of animal origin or in living animals, as
ell as for the anti-doping control of the human athletes or
acehorses.
[
[a Acta 589 (2007) 159–165
cknowledgment
The authors thank Professor Arthur Donny Strosberg (Scripps
esearch Institute, Florida, USA) for gently supplying a
ecombinant Escherichia coli strain expressing the human 2-
drenergic receptor.
This research was a FIRST-Europe project (MEDEBETA
o. EPH3310300R0242/215274) supported by the FEDER-FSE
bjective 3 Program and the Walloon Region (DGTRE).
eferences
[1] J.F. Martinez-Navarro, Lancet 336 (1990) 1311.
[2] G. Brambilla, A. Loizzo, L. Fontana, M. Strozzi, A. Guarino, V. Soprano,
JAMA (1997) 635.
[3] T.C. Shiu, W.H. Chong, Publ. Health Epidemiol. 10 (2001) 14.
[4] T. Visser, M.J. Vredenbregt, A.P. De Jong, H.J. van Rossum, R.W. Stephany,
L.A. van Ginkel, Analyst 119 (1994) 2681.
[5] K. De Wasch, H. De Brabander, D. Courtheyn, Analyst 123 (1998)
2701.
[6] G. Degand, A. Bernes-Duyckaerts, G. Maghuin-Rogister, J. Agric. Food
Chem. 40 (1992) 70.
[7] C.T. Elliott, W.J. McCaughey, H.D. Shortt, Food Addit. Contam. 10 (1993)
231.
[8] W. Haasnoot, L. Streppel, G. Cazemier, M. Salden, P. Stouten, M. Essers,
P. van Wichen, Analyst 121 (1996) 1111.
[9] M.A.J. Godfrey, P.L. Anderson, B. Ju¨licher, P. Kwasowski, M.J. Sauer,
in: N. Haagsma, A. Ruiter (Eds.), Proceedings Euroresidue III Conference
Veldhoven, University of Utrecht, Faculty of Veterinary Medicine, Utrecht,
The Netherlands, 1996, p. 421.
10] W. Haasnoot, P. Stouten, R. Schilt, D. Hooijerink, Analyst 123 (1998) 2707.
11] P. Delahaut, M. Dubois, I. Pri-Bar, O. Buchman, G. Degand, F. Ectors,
Food Addit. Contam. 8 (1991) 43.
12] I.M. Traynor, S.R.H. Crooks, J. Bowens, C.T. Elliott, Anal. Chim. Acta
483 (2003) 187.
13] D. Courtheyn, B. Le Bizec, G. Brambilla, H.F. De Brabander, E. Cobbaert,
M. Van de Wiele, J. Vercammen, K. De Wasch, Anal. Chim. Acta 473
(2002) 71.
14] U. Gether, Endocr. Rev. 21 (2000) 90.
15] S.S. Vansal, D.R. Feller, Biochem. Pharmacol. 58 (1999) 807.
16] R. Nagmani, D.S. Pasco, R.D. Salas, D.R. Feller, Biochem. Pharmacol. 65
(2003) 1489.
17] H. Reila¨nder, F. Boege, S. Vasudevan, G. Maul, M. Heckman, C. Dees, W.
Hampe, J.M. Helmreich, H. Michel, FEBS Lett. 282 (1991) 441.
18] S. Marullo, C. Delavier-Klutchko, Y. Eshdat, A.D. Strosberg, L. Emorine,
Proc. Natl. Acad. Sci. USA 85 (1988) 7551.
19] M.P. Chapot, Y. Eshdat, S. Marullo, J.G. Guillet, A. Charbit, A.D. Strosberg,
C. Klutchko-Delavier, Eur. J. Biochem. 187 (1990) 137.
20] V. Helbo, M. Vandenbroeck, G. Maghuin-Rogister, Arch. Lebensmittelhyg.
45 (1994) 57.
21] S.A. Meenagh, C.T. Elliott, R.K. Buick, C.A. Izeboud, R.F. Witkamp,
Analyst 126 (2001) 491.
22] C. Civitareale, C. Ambrosio, M. Sbraccia, M. Fiori, G. Brambilla, C. Testa,
Anal. Chim. Acta 529 (2005) 53.
23] V. Helbo, G. Degand, A. Duyckaerts, M.L. Scippo, G. Maghuin-Rogister,
in: L.A. van Ginkel, A. Ruiter (Eds.), Proceedings Euroresidue IV Confer-
ence Veldhoven, National Institute of Public Health and the Environment
(RIVM), Bilthoven, The Netherlands, 2000, p. 537.
24] S. Szmelcman, J.M. Cle´ment, M. Jehanno, O. Schwartz, L. Montagnier,
M. Hofnung, J. Acquir. Immune Defic. Syndr. 3 (1990) 859.
25] O.H. Lowry, N.J. Rosebrough, A.L. Farr, R.J. Randall, J. Biol. Chem. 193
(1951) 265.
26] G. Engels, D. Hoyer, R. Berthold, H. Wagner, Naunyn-Schmiedeberg’s
Arch. Pharmacol. 317 (1981) 277.
27] I. Moretti-Rojas, E.G. Ezrailson, L. Birnbaumer, M.L. Entman, A.J.J. Gar-





[S. Danyi et al. / Analytica C
28] G. Scatchard, Ann. N.Y. Acad. Sci. 51 (1949) 660.
29] E.C. Hulme, J.M. Birdsall, in: E.C. Hulme (Ed.), Receptor–Ligand Inter-
actions: A Practical Approach, Oxford University Press, Oxford, UK,
1992.




[a Acta 589 (2007) 159–165 165
31] R. Insoft, D.G. Sawutz, C.J. Homcy, Biochim. Biophys. Acta 861 (1986)
345.
32] B.K. Kobilka, Anal. Biochem. 231 (1995) 269.
33] A.L. Parola, S. Lin, B.K. Kobilka, Anal. Biochem. 254 (1997) 88.
34] W. Hampe, R.H. Voss, W. Haase, F. Boege, H. Michel, H. Reila¨nder, J.
Biotechnol. 77 (2000) 219.
